These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22215904)

  • 41. Resistance to Raf inhibition in cancer.
    Haarberg HE; Smalley KS
    Drug Discov Today Technol; 2014 Mar; 11():27-32. PubMed ID: 24847650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.
    Lemech C; Infante J; Arkenau HT
    Drugs; 2013 Jun; 73(8):767-77. PubMed ID: 23649971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New therapeutic targets in melanoma.
    Martí RM; Sorolla A; Yeramian A
    Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
    Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
    [No Abstract]   [Full Text] [Related]  

  • 45. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
    Verduzco D; Flaherty KT; Smalley KS
    Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
    [No Abstract]   [Full Text] [Related]  

  • 46. The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
    Filitis DC; Rauh J; Mahalingam M
    Melanoma Res; 2015 Dec; 25(6):470-8. PubMed ID: 26317169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted therapy for melanoma: is double hitting a home run?
    Smalley KS; Sondak VK
    Nat Rev Clin Oncol; 2013 Jan; 10(1):5-6. PubMed ID: 23207793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cell-based screening to detect inhibitors of BRAF signaling pathway.
    Asami Y; Mori M; Koshino H; Sekiyama Y; Teruya T; Simizu S; Usui T; Osada H
    J Antibiot (Tokyo); 2009 Feb; 62(2):105-7. PubMed ID: 19132054
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics.
    Smalley KS; Herlyn M
    Ann N Y Acad Sci; 2005 Nov; 1059():16-25. PubMed ID: 16382039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF inhibitor resistance can be overcome by blocking autophagy.
    Cancer Discov; 2014 May; 4(5):OF10. PubMed ID: 24795014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
    Catalanotti F; Solit DB
    Clin Cancer Res; 2012 May; 18(9):2420-2. PubMed ID: 22442059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitivity to anti-BRAF therapy: lost in translation.
    Kalkavan H; Goding CR
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):4-5. PubMed ID: 25220342
    [No Abstract]   [Full Text] [Related]  

  • 53. Fisetin: a natural fist against melanoma?
    Arbiser JL; Fisher DE
    J Invest Dermatol; 2011 Jun; 131(6):1187-9. PubMed ID: 21566577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
    Xu J; Regan-Fendt K; Deng S; Carson WE; Payne PRO; Li F
    Pac Symp Biocomput; 2018; 23():92-103. PubMed ID: 29218872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell Cycle Regulation and Melanoma.
    Xu W; McArthur G
    Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.
    Smalley KS; Aplin AE; Flaherty KT; Hoeller C; Bosserhoff AK; Haass NK; Bosenberg M; Ribas A; Barnhill R; Kudchadkar R; Messina JL
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):E1-11. PubMed ID: 22117673
    [No Abstract]   [Full Text] [Related]  

  • 57. The scope of nanoparticle therapies for future metastatic melanoma treatment.
    Bombelli FB; Webster CA; Moncrieff M; Sherwood V
    Lancet Oncol; 2014 Jan; 15(1):e22-32. PubMed ID: 24384491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic resistance: Fibroblasts restrain drug sensitivity.
    Alderton GK
    Nat Rev Cancer; 2015 Jun; 15(6):318-9. PubMed ID: 25998706
    [No Abstract]   [Full Text] [Related]  

  • 59. Melanoma: a model for testing new agents in combination therapies.
    Ascierto PA; Streicher HZ; Sznol M
    J Transl Med; 2010 Apr; 8():38. PubMed ID: 20406483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The malignant melanoma landscape.
    Webster RM; Mentzer SE
    Nat Rev Drug Discov; 2014 Jul; 13(7):491-2. PubMed ID: 24981356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.